Acute Repetitive Seizures (ARS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Acute Repetitive Seizures (ARS) Market Outlook

Thelansis’s “Acute Repetitive Seizures (ARS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Repetitive Seizures treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acute Repetitive Seizures (ARS) Overview

Seizure clusters, referred to as acute repetitive seizures, are frequent among individuals with epilepsy. These clusters can prove disruptive and burdensome for both patients and their caregivers. The criteria for defining seizure clusters involve two or more seizures within a 24-hour timeframe, which can span hours or even days. The primary risk factor associated with seizure clusters is the presence of intractable epilepsy characterized by a high average seizure frequency. Multifocal epilepsy, symptomatic generalized epilepsy, a previous history of central nervous system infections, and focal cortical dysplasia have all been identified as risk factors for experiencing seizure clusters. Acute repetitive seizures can manifest in various patterns, such as an increased frequency of auras, partial seizures, myoclonic jerks (generalized seizures), or two or more convulsions within a single day. These episodes of acute repetitive seizures can encompass any epileptic seizure and may even affect individuals with epilepsy who are managing their condition with stable anticonvulsant regimens. Many factors believed to trigger acute repetitive seizures overlap with those that can trigger other seizure types, including sleep deprivation, menstruation, infections, and fever. The only FDA-approved rescue medication for seizure clusters is rectal diazepam gel. However, other safe, effective, non-rectal, non-IV benzodiazepines can also treat acute seizures and clusters.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: